Effect of once-a-week vs thrice-a-week application of mupirocin on methicillin and mupirocin resistance in peritoneal dialysis patients: Three years of experience

Renal Failure

Volumn 30, Issue 4, 2008, Pages 417-422

  Cavdar, Caner ^a   Saglam, Funda ^a   Sifil, Aykut ^a   Celik, Ali ^a   Atay, Tugba ^a   Gungor, Ozkan ^a   Ozder, Ayse ^a   Gulay, Zeynep ^a   Camsari, Taner ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Exit site infection; Methicillin resistance; Mupirocin; Mupirocin resistance; Peritonitis

Indexed keywords

METICILLIN; PSEUDOMONIC ACID;

ADULT; ARTICLE; AXILLA; CLINICAL ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROL GROUP; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; INGUINAL REGION; LONG TERM CARE; MALE; MICROORGANISM; NOSE; PENICILLIN RESISTANCE; PERITONEAL DIALYSIS; PERITONITIS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, TOPICAL; AGED; CATHETERS, INDWELLING; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; EQUIPMENT CONTAMINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; LONG-TERM CARE; MALE; METHICILLIN; MIDDLE AGED; MUPIROCIN; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PERITONITIS; PROBABILITY; REFERENCE VALUES; RISK ASSESSMENT; STAPHYLOCOCCAL INFECTIONS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 45749118849     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220801964228     Document Type: Article

References (18)

1. Keogh AM. Complications in peritoneal dialysis peritonitis and exit site infections. Perit Dial Int. 1996;16:S:464-S467.
2. Fried LF, Bernardini J, Johnston JR, Piraino B. Peritonitis influences mortality in peritoneal dialysis patients. J Am Soc Nephrol. 1996;7(10):2176-2182.
3. Grupta B, Bernardini J, Piraino B. Peritonitis associated with exit site and tunnel infections. Am J Kidney Dis. 1996;28(3):415-419.
4. Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Moncalian J, Fernandez-Rivera C, Cao M, et al. Treatment of S. aureus nasal carriers in CAPD with mupirocin. Adv Perit Dial. 1992;8:242-245.
5. Bernardini J, Piraino B, Holley J, Juhnston JR, Lutes R. A randomized trial of S. aureus prophylaxis in peritoneal dialysis patients: Mupirocin calcium ointment 2% applied to exit site versus cyclic oral rifampin. Am J Kidney Dis. 1996;27:695-700.
6. Mahajan S, Tiwari S, Kalra V, Bhowmik D, Agarwal SK, Dash SC, et al. Effect of local mupirocin application on exit-site infection and peritonitis in an Indian peritoneal dialysis population. Perit Dial Int. 2005;25(5):473-477.
7. Uttley L, Vardhan A, Mahajan S, Smart B, Hutchinson A, Gokal R. Decrease in infections with the introduction of mupirocin cream at the peritoneal dialysis catheter exit-site. J Nephrol. 2004;17:242-245.
8. Twardowski ZJ, Prowant BF. Classification of normal and diseased exit sites. Perit Dial Int. 1996;3(Suppl.):S71-S76.
9. Piraino B, Bailie RG, Bernardini J, Boeschoten E, Gupta A, Holmes C, et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int. 2005;25:107-131.
10. Kiehlbauch JA, Hannett GE, Salfinger M, Archinal W, Monserrat C, Carlyn C. Use of the National Committee for Clinical Laboratory Standards Guidelines for disk diffusion susceptibility testing in New York state laboratories. J Clin Microbiol. 2000;38(9):3341-3348.
11. Thodis E, Bhaskaran S, Passadakis P, Bargman JM, Vas SI, Oreopoulos DG. Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at catheter exit site. Perit Dial Int. 1998;18:261-270.
12. Rosales M, Perez-Fontan M, Rodriguez-Carmona A, Garcia-Falcon T. Increasing resistance to mupirocin of S. aureus strains isolated from peritoneal dialysis patients and their partners: Long-term study. Perit Dial Int. 2001;2(Suppl.):218.
13. Annigeri R, Conly J, Vas S, Dedier H, Prakashan KP, Bargman JM, et al. Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Perit Dial Int. 2001;21:554-559.
14. Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Falcon TG, Valdes F. Mupirocin resistance after long-term use: Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis. 2002;39:337-341.
15. Lobbedez T, Gardam M, Dedier H, Burdzy D, Chu M, Izatt S, et al. Routine use of mupirocin at the peritoneal catheter exit site and mupirocin resistance. Still low after seven years. Nephrol Dial Transplant. 2004;19:3140-3143.
16. Kesli R, Cander S, Celebi S. Fusidic asit resistance of S. aureus. The Medical Journal of Kocatepe. 2004;5:33-36.
17. Refsalh K, Andersen BM. Clinically significant coagulase-negative staphylococci: Identification and resistance patterns. J Hosp Infect. 1992;22(1):19-31.
18. De mattos EM, Teixeria LA, Alves VM, Rezenda e Resende CA, da Silva Coimbra MV, da Silva-Carvalho MC, et al. Isolation of methicillin-resistant coagulase-negative staphylococci from patients undergoing continuous ambulatory peritoneal dialysis (CAPD) and comparison of different molecular techniques for discriminating isolates of Staphylococcus epidermidis. Diagn Microbiol Infect Dis. 2003;45(1):13-22.